Wellness program for neuromyelitis optica patients
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of NMOSD (using 2015 guidelines).
- You must not have had a relapse in the last 30 days.
- You must be able to give your own consent and take part in the study.
- You cannot be taking part in another trial or wellness program right now.
- If you start certain medications (like stimulants or dalfampridine) between signing up and starting the study, you won't be able to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMC-002 for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4+). It aims to see if IMC-002 is safe and effective at preventing attacks.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
This trial tests an antibody treatment for people having a neuromyelitis optica (NMO) relapse. It may reduce nerve damage from inflammation during an acute attack.
This study tests whether a new stem cell treatment (CE211NS21) is safe and well-tolerated in patients who have had a recent serious attack from NMOSD, a rare neurological condition. The treatment aims to reduce disability and vision loss from this disease.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
This trial tests a music-based walking therapy (called MR-C-014) to see if it is safe and well-tolerated for people with NMOSD who have trouble walking. It may help improve your walking pattern and strength.
Hear when a new Neuromyelitis Optica Spectrum Disorder (NMOSD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.